Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Noh T–W et al. – Tumors with high levels of expression of phospho–Akt and phospho–p44/42 MAPK and low levels of expression of phospho–CREB and ZAC1 should be followed closely and may require adjunctive therapy to prevent tumor recurrence.

Related Articles

Signalling Pathway Alterations in Pituitary Adenomas: Involvement of Gsalpha, cAMP and Mitogen-Activated Protein Kinases
Journal of Neuroendocrinology, 11/03/09    Relevance Score: 68%

Regulation of Pituitary Function by Cytokines
Hormone Research, 10/27/09    Relevance Score: 67%

Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer
Pituitary, 10/29/09    Relevance Score: 66%

Pituitary metastasis of Merkel cell carcinoma
Journal of Neuro-Oncology, 10/28/09    Relevance Score: 66%

The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas
Clinical Endocrinology, 10/15/09    Relevance Score: 65%

Today in Endocrine Oncology...keeping you current

Neuroendocrine carcinomas arising in solid-organ transplant recipients: rare but aggressive malignancies
Oncology (Karger), 11/25/09

Malignant teratoma of the thyroid in a pregnant woman
Annals of Diagnostic Pathology, 11/23/09

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
European Journal of Endocrinology, 11/19/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address